Research
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Jung-Won Suh, Bon-Kwon Koo, Shu-Ying Zhang, Kyung-Woo Park, Joo-Youn Cho, In-Jin Jang, Dong-Soon Lee, Dae-Won Sohn, Myoung-Mook Lee and Hyo-Soo Kim
CMAJ June 06, 2006 174 (12) 1715-1722; DOI: https://doi.org/10.1503/cmaj.060664
Jung-Won Suh
Bon-Kwon Koo
Shu-Ying Zhang
Kyung-Woo Park
Joo-Youn Cho
In-Jin Jang
Dong-Soon Lee
Dae-Won Sohn
Myoung-Mook Lee
Data supplements
Online Appendix
Files in this Data Supplement:
Related Articles
- (2006). Highlights of this issue. CMAJ, 174(12), 1693. Accessed March 18, 2024. Retrieved from http://www.cmaj.ca/content/174/12/1693.1.
- (2006). Dans ce numéro. CMAJ, 174(12), 1693-1693-a. Accessed March 18, 2024. Retrieved from http://www.cmaj.ca/content/174/12/1693.2.
- Turgeon, J., Pharand, C., & Michaud, V. (2006). Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism. CMAJ, 174(12), 1729. Accessed March 19, 2024. https://doi.org/10.1503/cmaj.060502.
In this issue
Article tools
Respond to this article
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Jung-Won Suh, Bon-Kwon Koo, Shu-Ying Zhang, Kyung-Woo Park, Joo-Youn Cho, In-Jin Jang, Dong-Soon Lee, Dae-Won Sohn, Myoung-Mook Lee, Hyo-Soo Kim
CMAJ Jun 2006, 174 (12) 1715-1722; DOI: 10.1503/cmaj.060664
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Jung-Won Suh, Bon-Kwon Koo, Shu-Ying Zhang, Kyung-Woo Park, Joo-Youn Cho, In-Jin Jang, Dong-Soon Lee, Dae-Won Sohn, Myoung-Mook Lee, Hyo-Soo Kim
CMAJ Jun 2006, 174 (12) 1715-1722; DOI: 10.1503/cmaj.060664
Jump to section
Related Articles
Cited By...
- Effect of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Impact on Modeling CYP3A-Mediated Drug-Drug Interactions
- Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention
- Formation of the Thiol Conjugates and Active Metabolite of Clopidogrel by Human Liver Microsomes
- Clopidogrel hyporesponsiveness: Are we all the same?
- Clopidogrel-Drug Interactions
- ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
- ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
- Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
- The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis From the PRINC (Plavix Response in Coronary Intervention) Trial
- Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
- Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
- Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes
- Atherothrombotic events and clopidogrel therapy
- Atherothrombotic events and clopidogrel therapy
- Atherothrombotic events and clopidogrel therapy
- Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol
- Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All?
- Corrections
- Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism